Last reviewed · How we verify
MSB0011359C
At a glance
| Generic name | MSB0011359C |
|---|---|
| Also known as | M7824 |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (PHASE1, PHASE2)
- Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma (PHASE1)
- HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (PHASE1, PHASE2)
- Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer (PHASE2)
- Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (PHASE2)
- M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (PHASE1, PHASE2)
- Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (PHASE2)
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSB0011359C CI brief — competitive landscape report
- MSB0011359C updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI